scholarly journals Concomitant Small Cell Neuroendocrine Carcinoma of Gallbladder and Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Paolo Aiello ◽  
Francesco Aragona ◽  
Valentina Territo ◽  
Anna Maria Caruso ◽  
Rosalia Patti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neuroendocrine Carcinoma ◽  
Incidental Finding ◽  
Case Reports ◽  
Lymph Node Biopsy ◽  
Small Cell ◽  
Neuroendocrine Neoplasm ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of The Gallbladder ◽  
Bioactive Agents

The neuroendocrine carcinoma is defined as a high-grade malignant neuroendocrine neoplasm arising from enterochromaffin cells, usually disposed in the mucosa of gastric and respiratory tracts. The localization in the gallbladder is rare. Knowledge of these gallbladder tumors is limited and based on isolated case reports. We describe a case of an incidental finding of small cell neuroendocrine carcinoma of the gallbladder, observed after cholecystectomy for cholelithiasis, in a 55-year-old female, who already underwent quadrantectomy and sentinel lymph-node biopsy for breast cancer. The patient underwent radiotherapy for breast cancer and six cycles of chemotherapy with cisplatin and etoposide. Eighteen months after surgery, the patient was free from disease. Small cell neuroendocrine carcinoma of the gallbladder has poor prognosis. Because of the rarity of the reported cases, specific prognostic factors have not been identified. The coexistence of small cell neuroendocrine carcinoma of the gallbladder with another malignancy has been reported only once. The contemporary presence of the two neoplasms could reflect that bioactive agents secreted by carcinoid can promote phenotypic changes in susceptible cells and induce neoplastic transformation.

scholarly journals Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Defeng Qing ◽  
Luxing Peng ◽  
Feng Cen ◽  
Xinjun Huang ◽  
Qiang Wei ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Checkpoint Inhibitors ◽  
Case Reports ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Literature Report ◽  
Free Survival ◽  
Hyperprogressive Disease

BackgroundPrimary small cell neuroendocrine carcinoma (SCNEC) in the ureter is extremely rare and has been sporadically reported in case reports. Its incidence, diagnosis, treatment, and outcomes have not yet been thoroughly understood. Here we present a patient with advanced SCNEC in the ureter who was treated by multimodal strategies. To the best of our knowledge, this is the first literature report about the clinical outcomes of the combination of programmed death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) and radiotherapy in patient with primary ureteral SCNEC.Case PresentationA 71-year old male presented with right flank pain and gross hematuria. A laparoscopic right nephroureterectomy was performed. He was diagnosed with primary ureteral SCNEC, pT3N0M0. Following the surgery, 4 cycles of adjuvant chemotherapy with carboplatin and etoposide (CE) were administered, with disease-free survival (DFS) of 10.1 months. He was then offered 4 cycles of palliative first-line chemotherapy with nedaplatin and irinotecan. The disease was continuously progressed, with progression-free survival (PFS) of 3.7 months. The patient subsequently received second-line treatment with PD-L1 ICI combined with radiotherapy. Unfortunately, hyperprogressive disease was found at the end of treatment. MRI and CT scan showed bilateral pubic bones, right acetabulum, and liver metastases. Without further intervention, the patient died from extensive metastatic disease 2 months after diagnosis, with overall survival (OS) of 18.2 months.ConclusionPhysicians must be aware of this rare and aggressive carcinoma at its initial presentation. Special attention should be paid to the potential likelihood of hyperprogression during the treatment.

scholarly journals Incidental finding of a small cell neuroendocrine carcinoma of the ureter

2019 ◽  
Vol 12 (7) ◽  
pp. e229290
Author(s):  
Obinna Obi-Njoku ◽  
Chris Bell ◽  
Prashant Ravindran Menon ◽  
Iqbal Shergill
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Multidisciplinary Team ◽  
Watchful Waiting ◽  
Incidental Finding ◽  
Small Cell ◽  
Review Of The Literature ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Urological Symptoms ◽  
Rare Site ◽  
Neuroendocrine Carcinomas

The ureter is an extremely rare site for small cell neuroendocrine carcinoma. We present a case of this disease in a patient who presented without urological symptoms. The multidisciplinary team proposed nephroureterectomy (if fit) or watchful waiting as management. After discussion with the patient a decision in favour of watchful waiting was made. We report her case including a review of the literature, and emphasise that although small cell neuroendocrine carcinomas can be very aggressive, they can remain asymptomatic.

scholarly journals A Case of Small Cell Neuroendocrine Carcinoma of the Esophagus after Radiotherapy for Breast Cancer

2013 ◽  
Vol 46 (6) ◽  
pp. 401-408 ◽  
Author(s):  
Daisuke Takeuchi ◽  
Naohiko Koide ◽  
Motohiro Okumura ◽  
Daisuke Komatsu ◽  
Akira Suzuki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of The Esophagus

Rare case of primary small-cell neuroendocrine breast carcinoma

2021 ◽  
Vol 14 (4) ◽  
pp. e237474
Author(s):  
Lina Pankratjevaite ◽  
Mette Holmqvist ◽  
Amuras Samulionis ◽  
Ute Hoyer
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Radiation Therapy ◽  
Breast Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Rare Case ◽  
Standard Treatment ◽  
Small Cell ◽  
The Body ◽  
Small Cell Neuroendocrine Carcinoma

Small-cell breast cancer is a very rare and aggressive type of neuroendocrine carcinoma. Histologically, it is indistinguishable from small-cell neuroendocrine lung cancer. Due to that, patients with small-cell neuroendocrine breast cancer should undergo examination of other areas of the body. Small-cell breast cancer may be treated with a combination of surgery, radiation therapy and chemotherapy. However, no standard treatment exists due to the small number of cases. We present a case of a 49-year-old woman with right breast primary small-cell neuroendocrine carcinoma.

Sign in / Sign up

Export Citation Format

Share Document